Quantitative Assessment of Antimalarial Activity in Vitro by a Semiautomated Microdilution Technique ROBERT E

Total Page:16

File Type:pdf, Size:1020Kb

Quantitative Assessment of Antimalarial Activity in Vitro by a Semiautomated Microdilution Technique ROBERT E ANTIMICROBIAL AGENTS AND CHEmOTHEzRAY, Dec. 1979, p. 710-718 Vol. 16, No.6 0066-4804/79/12-0710/09$2.00/0 Quantitative Assessment of Antimalarial Activity In Vitro by a Semiautomated Microdilution Technique ROBERT E. DESJARDINS,t* CRAIG J. CANFIELD,' J. DAVID HAYNES,2 AND JEFFREY D. CHULAY2 Department ofPharmacology' and Departnent ofImmunology,2 Walter Reed Army Institute ofResearch, Washington, DC 20012 Received for publication 10 September 1979 A rapid, semiautomated microdilution method was developed for measuring the activity of potential antimalarial drugs against cultured intraerythrocytic asexual forms of the human malaria parasite Plasmodium falciparum. Microti- tration plates were used to prepare serial dilutions of the compounds to be tested. Parasites, obtained from continuous stock cultures, were subcultured in these plates for 42 h. Inhibition of uptake of a radiolabeled nucleic acid precursor by the parasites served as the indicator of antimalarial activity. Results of repeated measurements of activity with chloroquine, quinine, and the investigational new drug mefloquine demonstrated that the method is sensitive and precise. Several additional antimalarial drugs and compounds of interest were tested in vitro, and the results were consistent with available in vivo data. The use of P. falciparum isolates with known susceptibility to antimalarial drugs also permitted evaluation of the cross-resistance potential of each compound tested. The applications and expectations of this new test system within a drug development program are discussed. The recent development of methods for the tem is partially automated for rapid analysis of continuous in vitro culture ofthe human malaria the data. parasite Plasmodium falciparum (4, 21) pro- vides a valuable resource for the investigation of MATERIALS AND METHODS new approaches to malaria chemotherapy. Di- Preparation of parasites. The parasite inocula rect measurement of the antimalarial activity of used in these experiments consisted of two isolates of potential new drugs against parasites grown in P. fakciparum. The African Uganda I strain was orig- vitro is now feasible. inally obtained by Martin and Arnold from a child in Kampala, Uganda, in 1965 (9). It has been widely used Resistance of P. fakciparum to chloroquine is in phase II clinical studies in human volunteers and an important consideration in the treatment and has retained its susceptibility to chloroquine, quinine, prevention ofmalaria in many parts ofthe world, and pyrimethamine. The Vietnam Smith strain, ob- including South and Central America (12), tained in 1969 from an American soldier at the Walter Southeast Asia (25), India (20), and the African Reed Army Medical Center, was first reported by continent (6). It is therefore essential to use well- Craig J. Canfield in 1971 (2). That patient, showing an characterized susceptible and resistant strains of R-I level of resistance to the combination of sulfalene the parasite in the evaluation of potential new and trimethoprim after treatment failures with other chemotherapeutic agents to detect cross-resist- antimalarial drugs, provided the parasite isolate des- standard anti- ignated Smith strain (2). This strain was later adapted ance with chloroquine and other to owl monkeys (24) and has also been used extensively malarial drugs. in human volunteer studies, where its resistance to The method described in this report can pro- chloroquine, quinine, and pyrimethamine has been vide quantitative measurements of the antima- amply documented (10). larial activity of large numbers of compounds, The two strains of parasites were grown continu- based on the inhibition of uptake of a radiola- ously in stock cultures by a modification of the meth- beled nucleic acid precursor by the parasite dur- ods of Trager and Jensen (21) and Haynes et al. (4). A ing short-term cultures in microtitration plates. 6% suspension of human type A+ erythrocytes was The parasites used are continually available prepared in culture medium which consisted of pow- The dered RMPI 1640 (GIBCO Laboratories, Grand Island, from long-tenn maintenance cultures. sys- N.Y.) diluted in sterile water with 25 mM HEPES (N- 2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; t Present address: Wellcome Research Laboratories, Re- Calbiochem, La Jolla, Calif.), 32 mM NaHCO3 search Triangle Park, NC 27709. (GIBCO), and 10% heat-inactivated (40 min at 56°C 710 VOL. 16, 1979 ASSESSMENT OF ANTIMALARIAL ACTIVITY IN VITRO 711 and then clarified by centrifugation) human type A+ i- fresh frozen plasma (in acid-citrate-dextrose antico- agulant). Stock cultures were maintained in 5.0 ml of the 6% erythrocyte suspension in 25-ml tissue culture CQOQO"O0KP""o flasks (Corning Glass Works, Corning, N.Y.). The o ~ 'OK ,>OqBQ1Q flasks were flushed with a gas mixture consisting of 5% 02, 5% C02, and 90% N2 (Air Products Corp., Allen- town, Pa.), sealed, and incubated at 370C. Best results were obtained in individual experiments when the F 88 growth rate in the stock cultures was high as indicated by a doubling of the parasitemia every 24 h. This was accomplished by daily changes of the culture medium and by dilution with fresh erythrocytes every 2 or 3 H QQQQQQQQQQQQ days so that less than 2% of the cells were infected at L any time. For each experiment, samples of the stock Li cultures were further diluted in culture medium con- FIG. 1. Representation of a microtiter plate, with taining sufficient noninfected type A+ human eryth- 96 wells arranged in 8 rows (A-H) and 12 columns rocytes to yield a final hematocrit of 1.5% and parasit- (1-12). When prepared as described in the text, wells emia of 0.25 to 0.5% in preparation for addition to the 1 through 8 of row A serve as a parasite control (no microtitration plates. drug present), and wells 9 through 12 of row A serve Preparation of drugs. Preparation of compounds as an erythrocyte control (no drug and no parasites). in a form suitable for addition to the microtitration Each compound ispresent in duplicate columns, over plate at a known concentration required consideration a 64-fold range, with the highest concentrations in of the aqueous solubility and sterility of each agent. row B and in twofold dilutions to the lowest concen- Many compounds were relatively insoluble in water trations in row H. and had to be dissolved initially in an organic solvent. These problems were overcome by using a combina- tion of sterile water and ethanol as the solvent. Each A constant volume (200 id) of the parasitized eryth- compound was first dissolved in a measured volume of rocyte suspension described above was added to each either water or ethanol, which was then diluted with well of the microtiter plate except the last four wells its counterpart to yield a 70% ethanol-30% water mix- of row A, to each of which 200 A1 of an equivalent ture containing a known concentration of the drug. suspension of nonparasitized type A+ human eryth- This solution was allowed to stand at room tempera- rocytes in culture medium was added. The total vol- ture for 30 min. Further dilutions were then made by ume in every well was then 225 pl. The first eight wells addition of the compound in the 70% ethanol solution of row A, containing no drugs, served as a parasite to a measured volume of culture medium with con- control. The last four wells of row A, containing nei- stant mixing. Plasma proteins in the culture medium ther drugs nor parasites, served as a nonparasitized presumably provided binding sites for compounds erythrocyte controL The parasitized erythrocytes were which might otherwise have precipitated in an exposed to each compound in two columns, with the aqueous solution. The final dilution contained less highest concentration in row B and the lowest concen- than 0.1% ethanol, which had no measurable effect on tration in row H. Two plates were prepared for each the parasites in this system. experiment; the Uganda I strain of the parasite was Preparation of microtitration plates. Microti- added to one, and the Smith strain was added to the tration techniques were used to measure the activity other. of a large number of compounds efficiently. The mi- After preparation as above, the plates were placed crotiter plate (Cooke Laboratory Products, Alexan- in a humidified airtight box (Instrumentation Depart- dria, Va.) used consisted of 96 flat-bottom wells, ar- ment, Walter Reed Army Institute ofResearch, Wash- ranged in a matrix of eight rows (A through H) and 12 ington, D.C.), which was then flushed with a gas columns (1 through 12) (Fig. 1). The plates were mixture of 5% 02,5% C02, and 90% N2 and sealed. The prepared and the parasites were harvested by using box was then placed in an incubator at 37°C for 24 h. strict aseptic techniques inside a laminar flow hood in Preparation of isotope and labeling of para- the following sequence. An Eppendorf pipette or a sites. Uptake of [G-3H]hypoxanthine (Amersham/ Microdrop I (Cooke Laboratory Products) multiple- Searle Corp., Arlington Heights, Ill.) was used as an well filling pipette was used to place 25 id ofthe culture index of growth of the parasites. The isotope is sup- medium in each well of the microtiter plate. Twenty- plied as a lyophylate (1,000 mCi/mmol) in ampoules five microliters of the drug solution, prepared as de- containing 1.0 mCi. The contents of a single ampoule scribed above, was then added to each of two adjacent were dissolved in 2.0 ml of 50% ethanol to provide a wells in the second row (B) ofthe plate. Six compounds stock solution which was stored at -20°C. In prepa- were thereby accommodated by each plate. After the ration for addition to the microtiter plates, the ethanol drugs were added to the wells of row B, an Automatic was evaporated from a 0.2-ml sample of the stock Diluter (Cooke Laboratory Products) was used to solution, and 4.9 ml of culture medium was added to make serial twofold dilutions across the plate in each the remaining 0.1 ml of the isotope in water.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Study Protocol, Statistical Analysis Plan, and Informed
    Protocol No. 01.05.2017 Confidential JULY 4, 2017 MUHAS/ KAROLINSKA INSTITUTET /UPPSALA UNIVERSITY Clinical Research Protocol “Aiming at prolonging the therapeutic life span of artemisinin-based combination therapies in an era of imminent Plasmodium falciparum resistance in Bagamoyo District, Tanzania - new strategies with old tools”. DR. LWIDIKO EDWARD MHAMILAWA- PHD STUDENT MUHAS Muhimbili University of Health and Allied Sciences Version Date: 04th July 2017 Page 1 of 92 Protocol No. 01.05.2017 Confidential MUHAS/ KAROLINSKA INSTITUTET /UPPSALA UNIVERSITY Clinical Research Protocol “Aiming at prolonging the therapeutic life span of artemisinin-based combination therapies in an era of imminent Plasmodium falciparum resistance in Bagamoyo District, Tanzania - new strategies with old tools”. Protocol Number: 01.05.2017 – ALU -PQ Version Date: 04th July 2017 Version 05 Investigational Product: Artemether-Lumefantrine and Primaquine Development Phase: Phase IV Sponsors: Muhimbili University of Health and Allied Sciences; Dept. of Parasitology and Medical Entomology P. O. Box 65001 Upanga, Dar es salaam Tanzania, Karolinska Institutet, Dept of Molecular, Tumor and Cell Biology, Nobelsväg 16 171 77 Stockholm, Sweden Uppsala University, Dept. of Women's and Children's Health, IMCH, Drottninggatan 4, 75310 Uppsala Sweden Funding Organization: Swedish International Development Agency (SIDA) & Swedish Research Council Principal Investigator: Name: Dr. Lwidiko Edward Mhamilawa Telephone: +255712865206 Fax: E-mail: [email protected] Version Date: 04th July 2017 Page 2 of 92 Protocol No. 01.05.2017 Confidential Co-investigators / Name: Dr. Billy Ngasala supervisors: Address: P.O Box 65011 DSM Mobile: 0754316359 Email:[email protected] Name: Prof. Anders Bjorkman Address: Solnavägen 1, 171 77 Solna, Sweden Mobile: +46 (0) 8-524 868 29.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,357,385 B2 Laronde Et Al
    US00835.7385B2 (12) United States Patent (10) Patent No.: US 8,357,385 B2 LaRonde et al. (45) Date of Patent: *Jan. 22, 2013 (54) COMBINATION THERAPY FOR THE FOREIGN PATENT DOCUMENTS TREATMENT OF BACTERAL INFECTIONS CA 2243 649 8, 1997 CA 2417 389 2, 2002 Inventors: Frank LaRonde, Toronto (CA); Hanje CA 2438 346 3, 2004 (75) CA 2539 868 4/2005 Chen, Toronto (CA); Selva Sinnadurai, CA 2467 321 11, 2005 Scarborough (CA) CA 2611 577 9, 2007 (73) Assignee: Interface Biologics Inc., Toronto (CA) OTHER PUBLICATIONS Bu et al. A Comparison of Topical Chlorhexidine, Ciprofloxacin, and (*) Notice: Subject to any disclaimer, the term of this Fortified Tobramycin/Cefazolin in Rabbit Models of Staphylococcus patent is extended or adjusted under 35 and Pseudomonas Keratitis. Journal of Ocular Pharmacology and U.S.C. 154(b) by 377 days. Therapeutics, 1997 vol. 23, No. 3, pp. 213-220.* Martin-Navarro et al. The potential pathogenicity of chlorhexidine This patent is Subject to a terminal dis sensittive Acanthamoeba strains isolated from contact lens cases claimer. from asymptomatic individuals in Tenerife, Canary Islands, Spain. Journal of Medical Microbiology. 2008. vol. 57, pp. 1399-1404.* (21) Appl. No.: 12/419,733 Craig et al., Modern Pharmacology. 4' Edition: 545-547, 555-557. 567, 569, 583-586, 651-654, and 849-851. (1994). Filed: Apr. 7, 2009 Jones et al., “Bacterial Resistance: A Worldwide Problem.” Diagn. (22) Microbiol. Infect. Dis. 31:379-388 (1998). Murray, "Antibiotic Resistance.” Adv. Intern. Med. 42:339-367 (65) Prior Publication Data (1997). US 201O/OO62974 A1 Mar. 11, 2010 Nakae, “Multiantibiotic Resistance Caused by Active Drug Extru sion in Pseudomonas aeruginosa and Other Gram-Negative Bacte ria.” Microbiologia.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.249,095 B2 Malladi Et Al
    US009249095 B2 (12) United States Patent (10) Patent No.: US 9.249,095 B2 Malladi et al. (45) Date of Patent: Feb. 2, 2016 (54) 2-METHYLTHIOPYRROLIDINES AND THEIR Andersen et al., gfp-based N-acyl homoserine-lactone sensor Sys USE FORMODULATING BACTERIAL tems for detection of bacterial communication, Appl. Environ. QUORUMSENSING Microbiol. 67(2):575-85 (2001). Andersen et al., New unstable variants of green fluorescent protein (75) Inventors: Venkata L. Malladi, Cranberry for studies of transient gene expression in bacteria, Appl. Environ. Township, PA (US); Lisa Schneper, Microbiol. 64(6):2240-6 (1998). Lititz, PA (US); Adam J. Sobczak, Bjarnsholt et al., Interference of Pseudomonas aeruginosa signalling Easley, SC (US); Kalai Mathee, Miami, and biofilm formation for infection control, Expert Rev. Mol. Med., 12:e11 (2010). FL (US); Stanislaw F. Wnuk, Miami, Bryk et al., Selective killing of nonreplicating mycobacteria, Cell FL (US) Host Microbe, 3(3):137-45 (2008). (73) Assignee: THE FLORIDA INTERNATIONAL Bryk et al., Triazaspirodimethoxybenzoyls as selective inhibitors of UNIVERSITY BOARD OF mycobacterial lipoamide dehydrogenase, Biochemistry, 49(8): 1616 27 (2010). TRUSTEES, Miami, FL (US) Casenghi et al., New approaches to filling the gap in tuberculosis drug discovery, PLoS Med., 4(11):e293 (2007). (*) Notice: Subject to any disclaimer, the term of this Chen et al., Structural identification of a bacterial quorum-sensing patent is extended or adjusted under 35 signal containing boron, Nature, 415(6871):545-9 (2002). U.S.C. 154(b) by 36 days. Chugani et al., QScR, a modulator of quorum-sensing signal synthe sis and virulence in Pseudomonas aeruginosa, Proc.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]